Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 11, 2026, 9:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 122 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: New Onset Clear all
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Study to Evaluate Efficacy of New Paracetamol Formulation Compared to Ibuprofen in Headache

NCT01842633
View directory record Official record
Conditions
Pain
Interventions
Paracetamol and Caffeine, Ibuprofen, Placebo
Drug · Other
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
365 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Waltham, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 31, 2017 · Synced Sep 11, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Novel Therapy to Preserve Beta Cell Function in New Onset Type 1 Diabetes

NCT00837759
View directory record Official record
Conditions
Diabetes Mellitus Type 1, Autoimmune Diabetes
Interventions
Insulin, Lansoprazole, Sitagliptin, Diamyd, GAD65 (Diamyd)
Drug · Biological
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
16 Years to 30 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 2, 2013 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 4 Interventional

Paravertebral Block to Reduce the Incidence of New Onset Atrial Fibrillation After Cardiac Surgery

NCT04472299
View directory record Official record
Conditions
New Onset Atrial Fibrillation, Anesthesia, Local, Cardiac Disease
Interventions
Ropivacaine 0.2% Injectable Solution
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced Sep 11, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients

NCT05188573
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Early detection pancreatic cancer test, Early detection pancreatic cancer test and MRI Imaging
Device
Lead sponsor
ClearNote Health
Industry
Eligibility
50 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Mar 26, 2026 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Autoimmunity-blocking Antibody for Tolerance in Recently Diagnosed Type 1 Diabetes

NCT00129259
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Anti-CD3 mAb, Diabetes Standard of Care Treatment, Iron supplementation
Biological · Other · Dietary Supplement
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 30 Years
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
7
States / cities
San Francisco, California • Denver, Colorado • New Haven, Connecticut + 3 more
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Sep 11, 2026, 9:41 AM EDT
Not listed Phase 1Phase 2 Interventional

Dendritic Cells for Type 1 Diabetes Mellitus (T1DM) Therapy

NCT01947569
View directory record Official record
Conditions
Treatment of Type I Diabetes Mellitus.
Interventions
Biological
Biological
Lead sponsor
DiaVacs, Inc.
Industry
Eligibility
12 Years to 35 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2013
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 22, 2013 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Results available

Canakinumab Study in Individuals With Newly Diagnosed Type 1 Diabetes

NCT00947427
View directory record Official record
Conditions
Type 1 Diabetes, Preservation of Insulin Secretion, Newly Diagnosed Type 1 Diabetes, Canakinumab in Type 1 Diabetes
Interventions
canakinumab (anti IL-1beta), Placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
6 Years to 45 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
11
States / cities
San Francisco, California • Stanford, California • New Haven, Connecticut + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2020 · Synced Sep 11, 2026, 9:41 AM EDT
Active, not recruiting Phase 2 Interventional

Rituximab-pvvr and Abatacept vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes

NCT03929601
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Rituximab-pvvr, Abatacept, Sterile Sodium Chloride
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
8 Years to 45 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
17
States / cities
Orange, California • Palo Alto, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 1 Interventional

MER3101: MAS-1 Adjuvanted Antigen-specific Immunotherapeutic for Prevention and Treatment of Type 1 Diabetes

NCT03624062
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
MAS-1 adjuvanted Insulin B-chain
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 45 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

New Onset Type 1 Diabetes: Role of Exenatide

NCT01269034
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Exenatide, Rapid and long acting insulin, long acting insulin + rapid acting + 1.25 mcg Exenatide
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

Study Looking at the Recovery of New Onset Cardiomyopathy

NCT00575211
View directory record Official record
Conditions
Cardiomyopathy
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
373 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2011
U.S. locations
14
States / cities
Orange, California • Gainesville, Florida • Baltimore, Maryland + 11 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2016 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 4 Interventional

INSPIRE Diabetes Study: Basal Bolus Insulin as Primary Treatment of Type 2 Diabetes

NCT01087567
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Intensive insulin, Routine Care
Drug
Lead sponsor
Ohio University
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Athens, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 20, 2014 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

Management of New-Onset Postoperative Atrial Fibrillation

NCT01395836
View directory record Official record
Conditions
Atrial Fibrillation, Coronary Artery Disease, Post Operative Arrythmia
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
Not listed
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

Effects of Chronic Antihypertensive Therapy on Clinical Outcomes in Septic Shock

NCT02876341
View directory record Official record
Conditions
Atrial Fibrillation, Septic Shock
Interventions
Not listed
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 12, 2017 · Synced Sep 11, 2026, 9:41 AM EDT
Withdrawn Phase 1Phase 2 Interventional

Safety and Efficacy Study of Amniotic Membrane Patch to Treat Postoperative Atrial Fibrillation

NCT02193321
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Amniotic Membrane Patch
Biological
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Dec 1, 2015 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

A Pharmaco-surgical Approach to Reduce Postoperative Atrial Fibrillation After Cardiac Surgery

NCT05780320
View directory record Official record
Conditions
Atrial Fibrillation New Onset
Interventions
Prophylactic amiodarone and posterior pericardiotomy
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Sep 11, 2026, 9:41 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Pilot Study Comparing the Efficacy and Safety of a New Pain Patch and Placebo in Delayed Onset Muscle Soreness (DOMS)

NCT02602353
View directory record Official record
Conditions
Delayed Onset Muscle Soreness
Interventions
Loxoprofen Pain Patch, Placebo Patch, No Treatment
Drug
Lead sponsor
Lead Chemical Co., Ltd.
Industry
Eligibility
18 Years to 40 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 27, 2016 · Synced Sep 11, 2026, 9:41 AM EDT
Active, not recruiting Phase 2 Interventional

Repeat BCG Vaccinations for the Treatment of New Onset Type 1 Diabetes in Children Age 8-<18 Years

NCT05866536
View directory record Official record
Conditions
Diabetes Mellitus, Type 1 Diabetes, Diabetes type1, Autoimmune Diabetes
Interventions
Bacillus Calmette-Guérin, Saline Injection
Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
1
States / cities
Charlestown, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Sep 11, 2026, 9:41 AM EDT
Terminated No phase listed Observational

A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

NCT03731637
View directory record Official record
Conditions
Diabetes, Type2 Diabetes, Diabetes Mellitus
Interventions
Not listed
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
50 Years to 85 Years
Enrollment
2,269 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 11, 2026, 9:41 AM EDT
Withdrawn Not applicable Interventional

Blood Pressure Effects of Nebivolol Versus Lisinopril in New Onset or Worsening Hypertension Induced by Bevacizumab

NCT01076140
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Lisinopril
Drug
Lead sponsor
University of Mississippi Medical Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Jackson, Mississippi
Source: ClinicalTrials.gov public record
Updated Apr 5, 2012 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

Examination of the Pancreas in New-onset Diabetes

NCT02001337
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
medical chart review, survey administration, Specimen collection
Other
Lead sponsor
Mayo Clinic
Other
Eligibility
50 Years to 85 Years
Enrollment
79 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 6, 2019 · Synced Sep 11, 2026, 9:41 AM EDT
Terminated Phase 2 Interventional Results available

Inducing Remission in Type 1 Diabetes With Alefacept

NCT00965458
View directory record Official record
Conditions
New-onset Type 1 Diabetes Mellitus
Interventions
Alefacept, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years to 35 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
15
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 11, 2026, 9:41 AM EDT
Terminated Phase 4 Interventional Results available

Using Sitagliptin as a Treatment to Prevent New Onset Diabetes After Kidney Transplantation

NCT00936663
View directory record Official record
Conditions
Type 2 Diabetes, End Stage Renal Disease
Interventions
Placebo, Sitagliptin
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 70 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 12, 2023 · Synced Sep 11, 2026, 9:41 AM EDT
Completed No phase listed Observational

Evaluation of StatNet Device for Electroencephalogram (EEG) Recordings

NCT03103425
View directory record Official record
Conditions
Epilepsy, Seizures
Interventions
Not listed
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Sep 11, 2026, 9:41 AM EDT